Literature DB >> 23509296

Critical role of miR-9 in myelopoiesis and EVI1-induced leukemogenesis.

Vitalyi Senyuk1, Yunyuan Zhang, Yang Liu, Ming Ming, Kavitha Premanand, Lan Zhou, Ping Chen, Jianjun Chen, Janet D Rowley, Giuseppina Nucifora, Zhijian Qian.   

Abstract

MicroRNA-9 (miR-9) is emerging as a critical regulator of organ development and neurogenesis. It is also deregulated in several types of solid tumors; however, its role in hematopoiesis and leukemogenesis is not yet known. Here we show that miR-9 is detected in hematopoietic stem cells and hematopoietic progenitor cells, and that its expression increases during hematopoietic differentiation. Ectopic expression of miR-9 strongly accelerates terminal myelopoiesis and promotes apoptosis in vitro and in vivo. Conversely, in hematopoietic progenitor cells, the inhibition of miR-9 with a miRNA sponge blocks myelopoiesis. Ecotropic viral integration site 1 (EVI1), required for normal embryogenesis, is considered an oncogene because its inappropriate up-regulation induces malignant transformation in solid and hematopoietic cancers. Here we show that EVI1 binds to the promoter of miR-9-3, leading to DNA hypermethylation of the promoter and repression of miR-9. Moreover, miR-9 expression reverses a myeloid differentiation block that is induced by EVI1. Our findings indicate that EVI1, when inappropriately expressed, delays or blocks myeloid differentiation at least in part by DNA hypermethylation and down-regulation of miR-9. It was reported that Forkhead box class O genes (FoxOs) inhibit myeloid differentiation and prevent differentiation of leukemia-initiating cells. Here we identify both FoxO1 and FoxO3 as direct targets of miR-9 in hematopoietic cells and find that up-regulation of FoxO3 inhibits miR-9-induced myelopoiesis. These results reveal a unique role of miR-9 in myelopoiesis and in the pathogenesis of EVI1-induced myeloid neoplasms and provide insights into the epigenetic regulation of miR9 in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23509296      PMCID: PMC3619279          DOI: 10.1073/pnas.1302645110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

Review 1.  MicroRNAs are shaping the hematopoietic landscape.

Authors:  Ute Bissels; Andreas Bosio; Wolfgang Wagner
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

2.  MicroRNA-9 directs late organizer activity of the midbrain-hindbrain boundary.

Authors:  Christoph Leucht; Christian Stigloher; Andrea Wizenmann; Ruth Klafke; Anja Folchert; Laure Bally-Cuif
Journal:  Nat Neurosci       Date:  2008-05-04       Impact factor: 24.884

3.  MiR-9 downregulates CDX2 expression in gastric cancer cells.

Authors:  Pichayanoot Rotkrua; Yoshimitsu Akiyama; Yutaka Hashimoto; Takeshi Otsubo; Yasuhito Yuasa
Journal:  Int J Cancer       Date:  2011-03-25       Impact factor: 7.396

4.  Methylation of microRNA-9 is a specific and sensitive biomarker for oral and oropharyngeal squamous cell carcinomas.

Authors:  Jacob Minor; Xiaotian Wang; Fang Zhang; John Song; Antonio Jimeno; Xiao-Jing Wang; Xian Lu; Neil Gross; Molly Kulesz-Martin; Daren Wang; Shi-Long Lu
Journal:  Oral Oncol       Date:  2011-11-30       Impact factor: 5.337

5.  A MicroRNA feedback circuit in midbrain dopamine neurons.

Authors:  Jongpil Kim; Keiichi Inoue; Jennifer Ishii; William B Vanti; Sergey V Voronov; Elizabeth Murchison; Gregory Hannon; Asa Abeliovich
Journal:  Science       Date:  2007-08-31       Impact factor: 47.728

6.  EVI1 induces myelodysplastic syndrome in mice.

Authors:  Silvia Buonamici; Donglan Li; Yiqing Chi; Rui Zhao; Xuerong Wang; Larry Brace; Hongyu Ni; Yogen Saunthararajah; Giuseppina Nucifora
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

7.  New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients.

Authors:  Detlef Haase; Ulrich Germing; Julie Schanz; Michael Pfeilstöcker; Thomas Nösslinger; Barbara Hildebrandt; Andrea Kundgen; Michael Lübbert; Regina Kunzmann; Aristoteles A N Giagounidis; Carlo Aul; Lorenz Trümper; Otto Krieger; Reinhard Stauder; Thomas H Müller; Friedrich Wimazal; Peter Valent; Christa Fonatsch; Christian Steidl
Journal:  Blood       Date:  2007-08-28       Impact factor: 22.113

8.  Evi1 is a survival factor which conveys resistance to both TGFbeta- and taxol-mediated cell death via PI3K/AKT.

Authors:  Y Liu; L Chen; T C Ko; A P Fields; E A Thompson
Journal:  Oncogene       Date:  2006-02-06       Impact factor: 9.867

9.  Down-regulated miR-9 and miR-433 in human gastric carcinoma.

Authors:  Hongchun Luo; Hongbin Zhang; Zhenzhen Zhang; Xia Zhang; Bo Ning; Jinjun Guo; Na Nie; Bo Liu; Xiaoling Wu
Journal:  J Exp Clin Cancer Res       Date:  2009-06-16

10.  Prediction of microRNAs affecting mRNA expression during retinal development.

Authors:  Amit Arora; Jasenka Guduric-Fuchs; Laura Harwood; Margaret Dellett; Tiziana Cogliati; David A Simpson
Journal:  BMC Dev Biol       Date:  2010-01-06       Impact factor: 1.978

View more
  34 in total

1.  New Lmna knock-in mice provide a molecular mechanism for the 'segmental aging' in Hutchinson-Gilford progeria syndrome.

Authors:  Hea-Jin Jung; Yiping Tu; Shao H Yang; Angelica Tatar; Chika Nobumori; Daniel Wu; Stephen G Young; Loren G Fong
Journal:  Hum Mol Genet       Date:  2013-11-07       Impact factor: 6.150

Review 2.  Posttranscriptional regulation of FOXO expression: microRNAs and beyond.

Authors:  P Urbánek; L-O Klotz
Journal:  Br J Pharmacol       Date:  2016-05-02       Impact factor: 8.739

Review 3.  MicroRNAs and acute myeloid leukemia: therapeutic implications and emerging concepts.

Authors:  Jared A Wallace; Ryan M O'Connell
Journal:  Blood       Date:  2017-07-27       Impact factor: 22.113

Review 4.  Role of microRNAs, circRNAs and long noncoding RNAs in acute myeloid leukemia.

Authors:  Yan Liu; Zhiheng Cheng; Yifan Pang; Longzhen Cui; Tingting Qian; Liang Quan; Hongyou Zhao; Jinlong Shi; Xiaoyan Ke; Lin Fu
Journal:  J Hematol Oncol       Date:  2019-05-24       Impact factor: 17.388

Review 5.  Regulation of microRNA function in somatic stem cell proliferation and differentiation.

Authors:  Archana Shenoy; Robert H Blelloch
Journal:  Nat Rev Mol Cell Biol       Date:  2014-08-13       Impact factor: 94.444

6.  miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia.

Authors:  Ping Chen; Colles Price; Zejuan Li; Yuanyuan Li; Donglin Cao; Anissa Wiley; Chunjiang He; Sandeep Gurbuxani; Rejani B Kunjamma; Hao Huang; Xi Jiang; Stephen Arnovitz; Mengyi Xu; Gia-Ming Hong; Abdel G Elkahloun; Mary Beth Neilly; Mark Wunderlich; Richard A Larson; Michelle M Le Beau; James C Mulloy; Paul P Liu; Janet D Rowley; Jianjun Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-24       Impact factor: 11.205

7.  Myeloid leukemia with high EVI1 expression is sensitive to 5-aza-2'-deoxycytidine by targeting miR-9.

Authors:  F Li; W He; R Geng; X Xie
Journal:  Clin Transl Oncol       Date:  2019-05-03       Impact factor: 3.405

8.  A decrease in hepatic microRNA-9 expression impairs gluconeogenesis by targeting FOXO1 in obese mice.

Authors:  Caifeng Yan; Jinfeng Chen; Min Li; Wenying Xuan; Dongming Su; Hui You; Yujie Huang; Nuoqi Chen; Xiubin Liang
Journal:  Diabetologia       Date:  2016-03-22       Impact factor: 10.122

9.  miR-9 and miR-263 Regulate the Key Genes of the ERK Pathway in the Ovary of Mud Crab Scylla paramamosain.

Authors:  Mingcan Zhou; Xiwei Jia; Haifu Wan; Shuhong Wang; Xin Zhang; Ziping Zhang; Yilei Wang
Journal:  Mar Biotechnol (NY)       Date:  2020-07-11       Impact factor: 3.619

10.  miR-9 is a tumor suppressor in pediatric AML with t(8;21).

Authors:  S Emmrich; J E Katsman-Kuipers; K Henke; M E Khatib; R Jammal; F Engeland; F Dasci; C M Zwaan; M L den Boer; L Verboon; J Stary; A Baruchel; V de Haas; A A Danen-van Oorschot; M Fornerod; R Pieters; D Reinhardt; J H Klusmann; M M van den Heuvel-Eibrink
Journal:  Leukemia       Date:  2013-11-25       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.